ethyl (4-acetylphenoxy)-acetate | 51828-69-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl (4-acetylphenoxy)-acetate
• 英文别名: ethyl 2-(4-acetylphenoxy)acetate
• CAS: 51828-69-4
• 化学式: C₁₂H₁₄O₄
• mdl: MFCD02269926
• 分子量: 222.241
• InChiKey: RVNWZMJGLXVZEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  343.1±17.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  ethyl (4-acetylphenoxy)-acetate 在 哌啶 、 盐酸 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 0.5h， 生成 (E)-ethyl 8-sec-butyl-6-(3-(4-(2-ethoxy-2-oxoethoxy)phenyl)-3-oxoprop-1-enyl)-2-oxo-2H-chromene-3-carboxylate
  参考文献：
  名称：

  Coumarin chalcone fibrates: A new structural class of lipid lowering agents

  摘要：

  In our continuing search for safe and efficacious antidyslipidemic agents, structurally interesting coumarin-chalcone fibrates were synthesized and evaluated in triton WR-1339 induced hyperlipidemic rats. The most active compound 41 decreased the total cholesterol (TC), phospholipids (PL) and triglycerides (TG), of hyperlipidemic rats by 26, 24, and 25% respectively. In addition, the compound 41 significantly reversed the levels of VLDL, LDL HDL and also increased the LPL activity. Altogether, our data suggests that these novel hybrids would be a potential new class of therapeutic agents against dyslipidemia. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.026
• 作为产物：
  描述：

  ethyl 4-(bromoacetyl)phenoxyacetate 在 水 、 1-methyl-3-pentyl-1H-imidazolium tetrafluoroborate 作用下， 125.0 ℃ 、344.74 kPa 条件下， 反应 0.07h， 以80%的产率得到ethyl (4-acetylphenoxy)-acetate
  参考文献：
  名称：

  Ionic liquid promoted selective debromination of α-bromoketones under microwave irradiation

  摘要：

  The debrontination of alpha-bromoketones with an easily accessible ionic liquid, 1-methyl-3-pentylimidazolium tetrafluoroborate, [pmIm]BF4 under microwave irradiation has been investigated. By controlling the reaction time gem-alpha-dibromoketones are selectively debrominated to either monobromo or debromoketones. The alpha-monobromo- and alpha-monoiodoketones are dehalogenated while the corresponding chloroketones remain inert. The activated vic-bromoacetates are converted to the corresponding (E)-alkenes by the same procedure. These reactions do not require any organic solvent, any metal or any conventional reducing agent. The ionic liquid works here as catalyst as well as reaction medium and is recycled without any appreciable loss of its catalytic efficiency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.10.035

文献信息

• .beta.-Adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols
  作者：M. S. Large、L. H. Smith

  DOI：10.1021/jm00176a002

  日期：1980.2

  series of derivatives of 1-phenyl-2-[[(substituted amido)alkyl]amino]ethanols is described. The compounds were investigated for beta-adrenoceptor blocking properties, and many showed a surprising degree of potency and beta 1-cardioselectivity when tested in vivo in anesthetized cats. The structure-activity relationships shown by this series of compounds are discussed and related to known beta-adrenergic

  描述了1-苯基-2-[[（取代的酰胺基烷基）氨基]氨基]乙醇的一系列衍生物的合成。研究了这些化合物的β-肾上腺素受体阻断特性，当在麻醉的猫体内进行测试时，许多化合物显示出令人惊讶的效力和β1-心脏选择性。讨论了这一系列化合物显示的结构活性关系，并与已知的β-肾上腺素能阻断剂有关。
• Thienopyridones as AMPK activators for the treatment of diabetes and obesity
  申请人：Iyengar R. Rajesh

  公开号：US20050038068A1

  公开（公告）日：2005-02-17

  The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.

  本发明涉及激活AMP-激活蛋白激酶（AMPK）的化合物，包括制备这些化合物、含有这些化合物的组合物以及利用这些化合物在预防或治疗糖尿病、代谢综合征和肥胖等疾病中的用途。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2011159297A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEURS GPR 120 ET LEURS APPLICATIONS
  申请人：METABOLEX INC

  公开号：WO2010080537A1

  公开（公告）日：2010-07-15

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• 4, 5-Dihydrooxazole-pyrazoline hybrids: Synthesis and their evaluation as potential antimalarial agents
  作者：Ashutosh Kumar Pandey、Supriya Sharma、Minakshi Pandey、M. Mumtaz Alam、M. Shaquiquzzaman、Mymoona Akhter

  DOI：10.1016/j.ejmech.2016.07.055

  日期：2016.11

  (3a-m) and substituted hydrazines in methanol. Some of the compounds exhibited promising in vitro antimalarial activity for chloroquine sensitive CQS (3D7) strain and chloroquine resistant CQR (RKL9) strain. The most potent analogue 4i (IC50 0.322 μg/ml) exhibited significant in vivo antimalarial potential against Plasmodium berghei mouse model. The stable complex of 4i with hematin (1:1 stoichiometry)

  通过取代的基于恶唑啉的查尔酮（3a-m）和取代的肼在甲醇中的缩合反应合成了一系列新的恶唑啉-吡唑啉杂化物（4a-p）。一些化合物对氯喹敏感的CQ S（3D7）菌株和耐氯喹的CQ R（RKL9）菌株显示出有希望的体外抗疟活性。最有效的类似物4i（IC 50 0.322μg/ ml）对伯氏疟原虫小鼠模型表现出显着的体内抗疟疾潜力。4i的稳定复合体血红素（化学计量比为1：1）表明血红素可能是这些杂合化合物的一种可能的靶标。该研究表明标题化合物具有潜在的抗疟药开发潜力。